Gossamer Bio, Inc.
US ˙ NasdaqGS ˙ US38341P1021

Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Otello Stampacchia. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at Otello Stampacchia har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed Titel Senest indberettede beholdninger
Director 454.982
US:LXEO / Lexeo Therapeutics, Inc. 10% Owner 2.157.623
US:REPL / Replimune Group, Inc. 10% Owner 4.673.380
US: / THESEUS PHARMACEUTICALS INC 0
US:KRON / Kronos Bio, Inc. Director, 10% Owner 20.600
US:MORF / Morphic Holding, Inc. Director 2.068.913
US:NUVB / Nuvation Bio Inc. 10% Owner 0
US:OMEG / Omega Alpha SPAC - Class A Chief Executive Officer, Director, 10% Owner 501.000
US:GOSS / Gossamer Bio, Inc. 10% Owner 6.737.023
US:IMUX / Immunic, Inc. 10% Owner 2.742.988
US:TBIO / Telesis Bio, Inc. 10% Owner 0
US:KZR / Kezar Life Sciences, Inc. 0
US:PRTK / Paratek Pharmaceuticals Inc. 10% Owner 12.043.945
Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Otello Stampacchia. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderkøb GOSS / Gossamer Bio, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i GOSS / Gossamer Bio, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

GOSS / Gossamer Bio, Inc. Insider Trades
Insidersalg GOSS / Gossamer Bio, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i GOSS / Gossamer Bio, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2019-09-18 GOSS Omega Fund V, L.P. 45.600 21,8780 45.600 21,8780 997.637 182 8 -632.836 -63,43
2019-09-17 GOSS Omega Fund V, L.P. 23.400 21,6150 23.400 21,6150 505.791
2019-09-16 GOSS Omega Fund V, L.P. 13.213 21,5190 13.213 21,5190 284.331
2019-09-11 GOSS Omega Fund V, L.P. 80.403 21,3130 80.403 21,3130 1.713.629
2019-09-10 GOSS Omega Fund V, L.P. 32.373 21,0010 32.373 21,0010 679.865
2019-09-06 GOSS Omega Fund V, L.P. 8.700 21,5061 8.700 21,5061 187.103
2019-09-05 GOSS Omega Fund V, L.P. 12.704 21,6022 12.704 21,6022 274.434

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

GOSS / Gossamer Bio, Inc. Insider Trades
Insiderkøb IMUX / Immunic, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i GOSS / Gossamer Bio, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

IMUX / Immunic, Inc. Insider Trades
Insidersalg IMUX / Immunic, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i GOSS / Gossamer Bio, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

IMUX / Immunic, Inc. Insider Trades
Insiderkøb KZR / Kezar Life Sciences, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i GOSS / Gossamer Bio, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

KZR / Kezar Life Sciences, Inc. Insider Trades
Insidersalg KZR / Kezar Life Sciences, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i GOSS / Gossamer Bio, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

KZR / Kezar Life Sciences, Inc. Insider Trades
Insiderkøb LXEO / Lexeo Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i GOSS / Gossamer Bio, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2023-11-07 LXEO Omega Fund VI, L.P. 454.545 11,0000 454.545 11,0000 4.999.995 219 18.7600 3.527.269 70,55

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

LXEO / Lexeo Therapeutics, Inc. Insider Trades
Insidersalg LXEO / Lexeo Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i GOSS / Gossamer Bio, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

LXEO / Lexeo Therapeutics, Inc. Insider Trades
Insiderkøb NUVB.WS / Panacea Acquisition Corp. - Equity Warrant – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i GOSS / Gossamer Bio, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

NUVB.WS / Panacea Acquisition Corp. - Equity Warrant Insider Trades
Insidersalg NUVB.WS / Panacea Acquisition Corp. - Equity Warrant – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i GOSS / Gossamer Bio, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

NUVB.WS / Panacea Acquisition Corp. - Equity Warrant Insider Trades
Insiderkøb REPL / Replimune Group, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i GOSS / Gossamer Bio, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2019-11-18 REPL Omega Fund IV, L.P. 220.000 13,6100 220.000 13,6100 2.994.200 365 48.9100 7.766.000 259,37
2018-07-24 REPL Omega Fund IV, L.P. 266.667 15,0000 266.667 15,0000 4.000.005

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

REPL / Replimune Group, Inc. Insider Trades
Insidersalg REPL / Replimune Group, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i GOSS / Gossamer Bio, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2022-03-16 REPL Omega Fund IV, L.P. 6.238 15,3100 6.238 15,3100 95.504 56 13.3200 -12.413 -13,00
2022-03-16 REPL Omega Fund IV, L.P. 38.762 15,5500 38.762 15,5500 602.749
2022-03-15 REPL Omega Fund IV, L.P. 45.000 15,6400 45.000 15,6400 703.800
2022-03-14 REPL Omega Fund IV, L.P. 16.500 15,4200 16.500 15,4200 254.430

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

REPL / Replimune Group, Inc. Insider Trades
Insiderkøb TBIO / Telesis Bio, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i GOSS / Gossamer Bio, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

TBIO / Telesis Bio, Inc. Insider Trades
Insidersalg TBIO / Telesis Bio, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i GOSS / Gossamer Bio, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

TBIO / Telesis Bio, Inc. Insider Trades
Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af Otello Stampacchia som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om
Del
Pris
Tran
Værdi
Tilbage
Værdi
2025-07-30 2025-07-25 4 IMA ImageneBio, Inc.
Common Stock
P - Purchase 267.556 454.982 142,75 29,90 7.999.924 13.603.962
2025-07-30 2025-07-25 4 IMA ImageneBio, Inc.
Common Stock
M - Exercise 379 379
2023-11-09 2023-11-07 4 LXEO Lexeo Therapeutics, Inc.
Common Stock
P - Purchase 454.545 2.157.623 26,69 11,00 4.999.995 23.733.853
2023-11-09 2023-11-07 4 LXEO Lexeo Therapeutics, Inc.
Common Stock
C - Conversion 287.213 1.703.078 20,29
2023-11-09 2023-11-07 4 LXEO Lexeo Therapeutics, Inc.
Common Stock
C - Conversion 1.415.865 1.415.865
2022-03-16 2022-03-16 4 REPL Replimune Group, Inc.
Common Stock
S - Sale -38.762 4.673.380 -0,82 15,55 -602.749 72.671.059
2022-03-16 2022-03-16 4 REPL Replimune Group, Inc.
Common Stock
S - Sale -6.238 4.712.142 -0,13 15,31 -95.504 72.142.894
2022-03-16 2022-03-15 4 REPL Replimune Group, Inc.
Common Stock
S - Sale -45.000 4.718.380 -0,94 15,64 -703.800 73.795.463
2022-03-16 2022-03-14 4 REPL Replimune Group, Inc.
Non-Qualified Stock Options
M - Exercise -16.500 16.500 -50,00
2022-03-16 2022-03-14 4 REPL Replimune Group, Inc.
Common Stock
S - Sale -16.500 4.763.380 -0,35 15,42 -254.430 73.451.320
2022-03-16 2022-03-14 4 REPL Replimune Group, Inc.
Common Stock
M - Exercise 16.500 4.779.880 0,35 9,78 161.370 46.747.226
2021-12-23 2021-12-21 4 IKNA Ikena Oncology, Inc.
Stock Option (Right to Buy)
A - Award 13.419 13.419
2021-11-23 2021-11-22 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -10.162 4.763.380 -0,21 34,70 -352.621 165.289.286
2021-11-23 2021-11-19 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -417 4.773.542 -0,01 34,80 -14.512 166.119.262
2021-11-23 2021-11-19 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -34.845 4.773.959 -0,72 34,54 -1.203.546 164.892.544
2021-11-18 2021-11-18 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -2.441 4.808.804 -0,05 33,50 -81.774 161.094.934
2021-11-18 2021-11-16 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -153 4.811.245 0,00 33,50 -5.126 161.176.708
2021-11-18 2021-11-18 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -2.441 4.808.804 -0,05 33,50 -81.774 161.094.934
2021-11-18 2021-11-16 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -153 4.811.245 0,00 33,50 -5.126 161.176.708
2021-11-16 2021-11-15 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -782 4.811.398 -0,02 33,66 -26.322 161.951.657
2021-11-16 2021-11-12 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -23.235 4.812.180 -0,48 33,66 -782.090 161.977.979
2021-11-12 2021-11-11 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -18.279 4.835.415 -0,38 33,61 -614.357 162.518.298
2021-11-12 2021-11-10 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -11 4.853.694 0,00 33,50 -368 162.598.749
2021-11-10 2021-11-09 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -7.537 4.853.705 -0,16 33,73 -254.223 163.715.470
2021-11-10 2021-11-08 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -3.817 4.861.242 -0,08 33,53 -127.984 162.997.444
2021-11-08 2021-11-05 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -5.790 4.865.059 -0,12 33,50 -193.965 162.979.476
2021-11-08 2021-11-04 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -25.225 4.870.849 -0,52 33,58 -847.056 163.563.109
2021-10-14 2021-10-12 4 THRX Theseus Pharmaceuticals, Inc.
Series B Preferred Stock
C - Conversion -693.152 0 -100,00
2021-10-14 2021-10-12 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock
P - Purchase 187.500 711.479 35,78 16,00 3.000.000 11.383.664
2021-10-14 2021-10-12 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock
C - Conversion 523.979 523.979
2021-09-27 2021-09-23 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -12.171 4.896.074 -0,25 33,58 -408.702 164.410.165
2021-09-20 2021-09-17 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -15.465 4.908.245 -0,31 33,71 -521.325 165.456.939
2021-09-20 2021-09-17 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -78.998 4.923.710 -1,58 32,88 -2.597.454 161.891.585
2021-09-20 2021-09-16 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -5.537 5.002.708 -0,11 32,55 -180.229 162.838.145
2021-06-23 2021-06-22 4 KRON Kronos Bio, Inc.
Stock Option (Right to Buy)
A - Award 20.600 20.600
2021-05-03 2021-04-30 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.855 2.068.913 -0,14 55,73 -159.109 115.300.521
2021-05-03 2021-04-30 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.274 2.071.768 -0,25 55,04 -290.281 114.030.111
2021-05-03 2021-04-30 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.358 2.077.042 -0,07 54,26 -73.685 112.700.299
2021-05-03 2021-04-29 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.114 2.078.400 -0,05 55,23 -61.526 114.790.032
2021-05-03 2021-04-29 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.731 2.079.514 -0,13 54,51 -148.867 113.354.308
2021-05-03 2021-04-29 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3.826 2.082.245 -0,18 53,37 -204.194 111.129.416
2021-04-29 2021-04-28 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.990 2.086.071 -0,10 55,96 -111.360 116.736.533
2021-04-29 2021-04-28 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.376 2.088.061 -0,07 55,36 -76.175 115.595.057
2021-04-29 2021-04-27 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -332 2.089.437 -0,02 56,28 -18.685 117.593.514
2021-04-29 2021-04-27 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.417 2.089.769 -0,21 55,62 -245.674 116.232.952
2021-04-29 2021-04-27 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.589 2.094.186 -0,12 54,60 -141.359 114.342.556
2021-04-27 2021-04-26 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.273 2.096.775 -0,06 57,28 -72.917 120.103.272
2021-04-27 2021-04-26 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.538 2.098.048 -0,12 56,71 -143.930 118.980.302
2021-04-27 2021-04-26 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.335 2.100.586 -0,06 55,54 -74.146 116.666.546
2021-04-27 2021-04-23 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1 2.101.921 0,00 57,43 -57 120.713.323
2021-04-27 2021-04-23 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.701 2.101.922 -0,08 56,50 -96.106 118.758.593
2021-04-27 2021-04-23 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3.838 2.103.623 -0,18 55,76 -214.007 117.298.018
2021-04-27 2021-04-23 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3.132 2.107.461 -0,15 55,11 -172.605 116.142.176
2021-04-23 2021-04-22 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -363 2.110.593 -0,02 59,75 -21.689 126.107.932
2021-04-23 2021-04-22 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.326 2.110.956 -0,11 59,37 -138.095 125.327.458
2021-04-23 2021-04-22 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.640 2.113.282 -0,08 57,88 -94.923 122.316.762
2021-04-23 2021-04-22 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.329 2.114.922 -0,25 57,08 -304.179 120.719.748
2021-04-23 2021-04-22 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.577 2.120.251 -0,12 56,34 -145.188 119.454.941
2021-04-23 2021-04-21 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3.523 2.122.828 -0,17 57,48 -202.502 122.020.153
2021-04-23 2021-04-21 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.991 2.126.351 -0,09 56,74 -112.969 120.649.156
2021-04-23 2021-04-21 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -109 2.128.342 -0,01 55,15 -6.011 117.378.061
2021-04-23 2021-04-21 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.929 2.128.451 -0,09 53,76 -103.703 114.425.526
2021-04-21 2021-04-20 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -76 2.130.380 0,00 55,54 -4.221 118.321.305
2021-04-21 2021-04-20 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.374 2.130.456 -0,20 54,88 -240.045 116.919.425
2021-04-21 2021-04-20 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.343 2.134.830 -0,25 54,07 -288.896 115.430.258
2021-04-21 2021-04-19 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -809 2.140.173 -0,04 54,66 -44.220 116.981.856
2021-04-21 2021-04-19 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -7.272 2.140.982 -0,34 54,06 -393.124 115.741.487
2021-04-19 2021-04-16 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.719 2.148.254 -0,13 55,36 -150.524 118.927.341
2021-04-19 2021-04-16 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3.846 2.150.973 -0,18 54,37 -209.107 116.948.402
2021-04-19 2021-04-15 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -355 2.154.819 -0,02 58,11 -20.629 125.216.532
2021-04-19 2021-04-15 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.828 2.155.174 -0,13 57,15 -161.620 123.168.194
2021-04-19 2021-04-15 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.331 2.158.002 -0,20 56,10 -242.969 121.063.912
2021-04-19 2021-04-15 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3.667 2.162.333 -0,17 55,16 -202.272 119.274.288
2021-04-15 2021-04-14 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.064 2.166.000 -0,19 58,95 -239.573 127.685.700
2021-04-15 2021-04-14 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3.716 2.170.064 -0,17 58,08 -215.825 126.037.317
2021-04-15 2021-04-14 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.055 2.173.780 -0,09 56,95 -117.032 123.796.771
2021-04-15 2021-04-14 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.097 2.175.835 -0,19 55,88 -228.940 121.585.660
2021-04-15 2021-04-13 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -367 2.179.932 -0,02 58,25 -21.378 126.981.039
2021-04-15 2021-04-13 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.879 2.180.299 -0,22 57,61 -281.079 125.607.025
2021-04-15 2021-04-13 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.758 2.185.178 -0,08 56,70 -99.679 123.899.593
2021-04-13 2021-04-12 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -708 2.186.936 -0,03 59,07 -41.822 129.182.310
2021-04-13 2021-04-12 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -7.735 2.187.644 -0,35 57,46 -444.453 125.702.024
2021-04-13 2021-04-12 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -6.149 2.195.379 -0,28 56,84 -349.509 124.785.342
2021-04-13 2021-04-09 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -35 2.201.528 0,00 61,41 -2.149 135.195.834
2021-04-13 2021-04-09 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.830 2.201.563 -0,08 60,05 -109.892 132.203.858
2021-04-13 2021-04-09 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.229 2.203.393 -0,24 59,19 -309.505 130.418.832
2021-04-13 2021-04-09 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3.126 2.208.622 -0,14 58,13 -181.714 128.387.197
2021-04-09 2021-04-08 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -10.491 2.211.748 -0,47 60,98 -639.741 134.872.393
2021-04-09 2021-04-08 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.745 2.222.239 -0,21 60,48 -286.978 134.401.015
2021-04-09 2021-04-07 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.172 2.226.984 -0,23 61,01 -315.544 135.868.294
2021-04-09 2021-04-07 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -6.277 2.232.156 -0,28 60,51 -379.821 135.067.760
2021-04-07 2021-04-06 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -65 2.238.433 0,00 62,21 -4.044 139.252.917
2021-04-07 2021-04-06 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3.543 2.238.498 -0,16 61,48 -217.824 137.622.857
2021-04-07 2021-04-06 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -7.273 2.242.041 -0,32 60,93 -443.144 136.607.558
2021-04-07 2021-04-05 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.192 2.249.314 -0,05 64,71 -77.134 145.553.109
2021-04-07 2021-04-05 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.354 2.250.506 -0,06 63,13 -85.478 142.074.444
2021-04-07 2021-04-05 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3.918 2.251.860 -0,17 61,79 -242.093 139.142.429
2021-04-07 2021-04-05 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3.079 2.255.778 -0,14 61,05 -187.973 137.715.247
2021-04-05 2021-04-01 4 REPL Replimune Group, Inc.
Stock Option (Right to Buy)
A - Award 16.500 16.500
2021-04-02 2021-04-01 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.312 2.258.857 -0,06 66,01 -86.605 149.107.151
2021-04-02 2021-04-01 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -9.303 2.260.169 -0,41 65,19 -606.463 147.340.417
2021-04-02 2021-04-01 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.064 2.269.472 -0,09 64,44 -133.004 146.244.776
2021-04-02 2021-04-01 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -942 2.271.536 -0,04 62,89 -59.242 142.856.899
2021-04-02 2021-03-31 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -112 2.272.478 0,00 63,97 -7.165 145.370.418
2021-04-02 2021-03-31 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -11.560 2.272.590 -0,51 63,34 -732.210 143.945.851
2021-04-02 2021-03-31 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.112 2.284.150 -0,22 62,45 -319.244 142.645.168
2021-04-01 2021-03-30 4 IKNA Ikena Oncology, Inc.
Series B Preferred Stock
C - Conversion -12.870.933 0 -100,00
2021-04-01 2021-03-30 4 IKNA Ikena Oncology, Inc.
Common Stock
A - Award 450.000 2.249.123 25,01 16,00 7.200.000 35.985.968
2021-04-01 2021-03-30 4 IKNA Ikena Oncology, Inc.
Common Stock
C - Conversion 1.799.123 1.799.123
2021-04-01 2020-12-21 4 IKNA Ikena Oncology, Inc.
Series B Preferred Stock
A - Award 12.870.933 12.870.933 1,40 18.000.000 18.000.000
2021-03-31 2021-03-30 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -382 2.289.262 -0,02 63,28 -24.173 144.864.499
2021-03-31 2021-03-30 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.691 2.289.644 -0,25 62,74 -357.053 143.652.265
2021-03-31 2021-03-30 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -9.413 2.295.335 -0,41 61,73 -581.064 141.691.030
2021-03-31 2021-03-30 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.433 2.304.748 -0,06 60,82 -87.155 140.174.773
2021-03-31 2021-03-30 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -581 2.306.181 -0,03 59,16 -34.372 136.433.668
2021-03-31 2021-03-30 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.408 2.306.762 -0,10 58,18 -140.097 134.207.413
2021-03-31 2021-03-29 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -8 2.309.170 0,00 60,88 -487 140.582.270
2021-03-31 2021-03-29 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.814 2.309.178 -0,12 60,06 -169.009 138.689.231
2021-03-31 2021-03-29 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.551 2.311.992 -0,24 59,12 -328.175 136.684.967
2021-03-31 2021-03-29 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -7.795 2.317.543 -0,34 58,24 -453.981 134.973.704
2021-03-29 2021-03-26 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.406 2.325.338 -0,06 61,14 -85.963 142.171.165
2021-03-29 2021-03-26 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.572 2.326.744 -0,20 60,10 -274.777 139.837.314
2021-03-29 2021-03-26 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -7.003 2.331.316 -0,30 59,22 -414.718 138.060.534
2021-03-29 2021-03-25 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -416 2.338.319 -0,02 60,86 -25.318 142.310.094
2021-03-29 2021-03-25 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -6.372 2.338.735 -0,27 60,43 -385.060 141.329.756
2021-03-29 2021-03-25 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.087 2.345.107 -0,17 59,02 -241.215 138.408.215
2021-03-29 2021-03-25 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -11.257 2.349.194 -0,48 58,21 -655.270 136.746.583
2021-03-29 2021-03-25 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -8.820 2.360.451 -0,37 57,24 -504.857 135.112.215
2021-03-29 2021-03-25 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.004 2.369.271 -0,17 56,28 -225.345 133.342.572
2021-03-25 2021-03-24 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.368 2.373.275 -0,18 62,54 -273.175 148.424.618
2021-03-25 2021-03-24 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.043 2.377.643 -0,21 61,52 -310.245 146.272.597
2021-03-25 2021-03-24 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.289 2.382.686 -0,18 60,38 -258.970 143.866.581
2021-03-25 2021-03-24 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.736 2.386.975 -0,20 59,38 -281.224 141.738.576
2021-03-25 2021-03-24 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -8.280 2.391.711 -0,35 58,18 -481.730 139.149.746
2021-03-25 2021-03-24 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -6.255 2.399.991 -0,26 57,05 -356.848 136.919.487
2021-03-25 2021-03-23 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.444 2.406.246 -0,06 63,66 -91.925 153.181.620
2021-03-25 2021-03-23 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -6.912 2.407.690 -0,29 62,70 -433.382 150.962.163
2021-03-25 2021-03-23 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -9.236 2.414.602 -0,38 61,94 -572.078 149.560.448
2021-03-25 2021-03-23 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.751 2.423.838 -0,07 60,81 -106.478 147.393.589
2021-03-23 2021-03-22 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.406 2.425.589 -0,06 65,51 -92.107 158.900.335
2021-03-23 2021-03-22 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.996 2.426.995 -0,25 64,99 -389.680 157.730.405
2021-03-23 2021-03-22 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.751 2.432.991 -0,07 63,98 -112.029 155.662.764
2021-03-23 2021-03-19 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.848 2.434.742 -0,12 64,69 -184.237 157.503.460
2021-03-23 2021-03-19 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.836 2.437.590 -0,24 64,00 -373.504 156.005.760
2021-03-23 2021-03-19 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.026 2.443.426 -0,21 63,01 -316.688 153.960.272
2021-03-23 2021-03-19 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.919 2.448.452 -0,12 61,92 -180.744 151.608.148
2021-03-19 2021-03-18 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.083 2.451.371 -0,04 64,58 -69.940 158.309.539
2021-03-19 2021-03-18 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -15.154 2.452.454 -0,61 64,02 -970.159 157.006.105
2021-03-19 2021-03-18 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3.235 2.467.608 -0,13 63,00 -203.805 155.459.304
2021-03-19 2021-03-17 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -993 2.470.843 -0,04 65,26 -64.803 161.247.214
2021-03-19 2021-03-17 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -8.087 2.471.776 -0,33 64,59 -522.339 159.652.012
2021-03-19 2021-03-17 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -7.301 2.479.863 -0,29 63,72 -465.220 158.016.870
2021-03-17 2021-03-16 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.394 2.487.164 -0,06 68,33 -95.252 169.947.916
2021-03-17 2021-03-16 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -197 2.488.558 -0,01 66,47 -13.095 165.414.450
2021-03-17 2021-03-16 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -692 2.488.755 -0,03 65,55 -45.361 163.137.890
2021-03-17 2021-03-16 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -6.483 2.489.447 -0,26 64,44 -417.765 160.419.965
2021-03-17 2021-03-16 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -14.777 2.495.930 -0,59 63,72 -941.590 159.040.660
2021-03-17 2021-03-16 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.316 2.510.707 -0,17 62,52 -269.836 156.969.402
2021-03-17 2021-03-15 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.112 2.515.023 -0,08 69,13 -146.003 173.863.540
2021-03-17 2021-03-15 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.630 2.517.125 -0,10 67,96 -178.735 171.063.815
2021-03-17 2021-03-15 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -10.825 2.519.765 -0,43 66,94 -724.626 168.673.069
2021-03-17 2021-03-15 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -6.620 2.530.590 -0,26 66,06 -437.317 167.170.775
2021-03-17 2021-03-15 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.004 2.537.210 -0,16 64,78 -259.379 164.360.464
2021-03-17 2021-03-15 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -10.341 2.541.214 -0,41 63,97 -661.514 162.561.460
2021-03-01 2021-03-01 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -600 2.551.555 -0,02 47,12 -28.272 120.229.272
2021-03-01 2021-03-01 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.692 2.552.155 -0,11 46,28 -124.586 118.113.733
2021-03-01 2021-03-01 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3.772 2.554.847 -0,15 45,49 -171.588 116.219.990
2021-03-01 2021-02-26 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3.604 2.558.619 -0,14 35,93 -129.492 91.931.181
2021-03-01 2021-02-26 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -7.808 2.562.223 -0,30 35,27 -275.388 90.369.605
2021-03-01 2021-02-26 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.458 2.570.031 -0,21 34,28 -187.100 88.100.663
2021-03-01 2021-02-26 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.376 2.575.489 -0,09 32,87 -78.099 84.656.323
2021-03-01 2021-02-25 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -242 2.577.865 -0,01 35,32 -8.547 91.050.192
2021-03-01 2021-02-25 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.013 2.578.107 -0,08 34,39 -69.227 88.661.100
2021-03-01 2021-02-25 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -7.424 2.580.120 -0,29 33,46 -248.407 86.330.815
2021-02-25 2021-02-24 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.431 2.587.544 -0,09 34,89 -84.818 90.279.410
2021-02-25 2021-02-24 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -567 2.589.975 -0,02 34,27 -19.431 88.758.443
2021-02-25 2021-02-23 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.052 2.590.542 -0,08 34,36 -70.507 89.011.023
2021-02-25 2021-02-23 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.498 2.592.594 -0,21 33,75 -185.558 87.500.048
2021-02-23 2021-02-22 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -785 2.598.092 -0,03 35,72 -28.040 92.803.846
2021-02-23 2021-02-22 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.638 2.598.877 -0,22 34,80 -196.202 90.440.920
2021-02-23 2021-02-19 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -540 2.604.515 -0,02 36,50 -19.710 95.064.798
2021-02-23 2021-02-19 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.871 2.605.055 -0,07 36,12 -67.581 94.094.587
2021-02-23 2021-02-19 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.025 2.606.926 -0,08 34,82 -70.510 90.773.163
2021-02-19 2021-02-18 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -928 2.608.951 -0,04 35,76 -33.185 93.296.088
2021-02-19 2021-02-18 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -7.966 2.609.879 -0,30 34,83 -277.456 90.902.086
2021-02-19 2021-02-17 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -7.262 2.617.845 -0,28 35,93 -260.924 94.059.171
2021-02-17 2021-02-16 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.162 2.625.107 -0,04 37,25 -43.284 97.785.236
2021-02-17 2021-02-16 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.863 2.626.269 -0,18 36,42 -177.110 95.648.717
2021-02-17 2021-02-12 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -776 2.631.132 -0,03 38,21 -29.651 100.535.554
2021-02-17 2021-02-12 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.588 2.631.908 -0,06 37,47 -59.502 98.617.593
2021-02-12 2021-02-11 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -17 2.633.496 0,00 38,08 -647 100.283.528
2021-02-12 2021-02-11 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3.988 2.633.513 -0,15 37,76 -150.587 99.441.451
2021-02-12 2021-02-10 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.046 2.637.501 -0,04 38,49 -40.261 101.517.413
2021-02-12 2021-02-10 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.022 2.638.547 -0,19 37,34 -187.521 98.523.345
2021-02-12 3 NUVB Nuvation Bio Inc.
No securities owned.
0
2021-02-12 2021-02-10 4 NUVB Nuvation Bio Inc.
Series A Preferred Stock
C - Conversion -8.130.097 0 -100,00
2021-02-12 2021-02-10 4 NUVB Nuvation Bio Inc.
Class A Common Stock
A - Award 500.000 28.212.373 1,80 10,00 5.000.000 282.123.730
2021-02-12 2021-02-10 4 NUVB Nuvation Bio Inc.
Class A Common Stock
C - Conversion 8.130.097 27.712.373 41,52
2021-02-11 2021-02-08 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -5.249 5.141.321 -0,10 45,00 -236.205 231.359.445
2021-02-10 2021-02-09 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.148 2.643.569 -0,04 40,37 -46.345 106.720.881
2021-02-10 2021-02-09 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.313 2.644.717 -0,16 39,76 -171.485 105.153.948
2021-02-10 2021-02-08 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -12.554 2.649.030 -0,47 39,83 -500.026 105.510.865
2021-02-10 2021-02-08 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.068 2.661.584 -0,15 38,80 -157.838 103.269.459
2021-02-08 2021-02-05 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -147 2.673.902 -0,01 38,40 -5.645 102.677.837
2021-02-08 2021-02-05 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.734 2.674.049 -0,21 37,78 -216.631 101.025.571
2021-02-08 2021-02-04 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.963 2.679.783 -0,18 38,55 -191.324 103.305.635
2021-02-08 2021-02-04 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.574 2.684.746 -0,17 37,95 -173.583 101.886.111
2021-02-04 2021-02-03 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -8.586 2.689.320 -0,32 38,63 -331.677 103.888.432
2021-02-04 2021-02-03 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -17.572 2.697.906 -0,65 38,05 -668.615 102.655.323
2021-02-04 2021-02-02 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -669 2.715.478 -0,02 37,16 -24.860 100.907.162
2021-02-04 2021-02-02 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -7.362 2.716.147 -0,27 36,74 -270.480 99.791.241
2021-02-04 2021-02-02 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -19.935 2.723.509 -0,73 35,61 -709.885 96.984.155
2021-02-02 2021-02-01 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.160 2.743.444 -0,04 34,87 -40.449 95.663.892
2021-02-02 2021-02-01 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.166 2.744.604 -0,19 34,38 -177.607 94.359.486
2021-02-02 2021-02-01 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3.883 2.749.770 -0,14 33,31 -129.343 91.594.839
2021-02-02 2021-01-29 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -449 2.753.653 -0,02 34,00 -15.266 93.624.202
2021-02-02 2021-01-29 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -9.885 2.754.102 -0,36 33,41 -330.258 92.014.548
2021-01-29 2021-01-28 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -6.987 2.763.987 -0,25 33,67 -235.252 93.063.442
2021-01-29 2021-01-28 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -4.274 2.770.974 -0,15 33,09 -141.427 91.691.530
2021-01-29 2021-01-27 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.941 2.775.248 -0,11 32,37 -95.200 89.834.778
2021-01-29 2021-01-27 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -6.534 2.778.189 -0,23 31,78 -207.651 88.290.846
2021-01-28 2021-01-26 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -3.393 5.283.682 -0,06 46,04 -156.214 243.260.719
2021-01-28 2021-01-26 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -26.957 5.287.075 -0,51 45,34 -1.222.230 239.715.980
2021-01-27 2021-01-26 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.438 2.784.723 -0,09 32,91 -80.235 91.645.234
2021-01-27 2021-01-26 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -6.848 2.787.263 -0,25 32,25 -220.848 89.889.232
2021-01-27 2021-01-25 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.504 2.794.111 -0,05 31,48 -47.346 87.958.614
2021-01-27 2021-01-25 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.119 2.795.615 -0,18 30,88 -158.075 86.328.591
2021-01-26 2021-01-22 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -3.269 5.314.032 -0,06 45,03 -147.203 239.290.861
2021-01-26 2021-01-22 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -8.090 5.317.301 -0,15 45,05 -364.454 239.544.410
2021-01-25 2021-01-22 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.438 2.800.734 -0,09 31,11 -75.846 87.130.835
2021-01-25 2021-01-22 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -7.303 2.803.172 -0,26 30,64 -223.764 85.889.190
2021-01-25 2021-01-21 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -264 2.810.475 -0,01 29,98 -7.915 84.258.040
2021-01-21 2021-01-19 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -6.506 2.810.739 -0,23 29,95 -194.855 84.181.633
2021-01-21 2021-01-19 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -10.732 2.817.245 -0,38 30,10 -323.033 84.799.074
2021-01-19 2021-01-15 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -1.916 5.325.391 -0,04 45,19 -86.584 240.654.419
2021-01-19 2021-01-14 4 REPL Replimune Group, Inc.
Common Stock
S - Sale X -17.664 5.327.307 -0,33 45,09 -796.470 240.208.273
2021-01-19 2021-01-15 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -14.289 2.827.977 -0,50 30,49 -435.672 86.225.019
2021-01-19 2021-01-14 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3.904 2.842.266 -0,14 31,06 -121.258 88.280.782
2021-01-19 2021-01-14 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.337 2.848.170 -0,19 30,27 -161.551 86.214.106
2021-01-15 2021-01-13 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -6.740 2.851.507 -0,24 30,11 -202.941 85.858.876
2021-01-15 2021-01-12 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5.758 2.858.247 -0,20 30,10 -173.316 86.033.235
2021-01-13 2021-01-11 4 OMEG Omega Alpha SPAC
Class A Ordinary Shares
P - Purchase 501.000 501.000 10,00 5.010.000 5.010.000
2021-01-12 2021-01-11 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3.382 2.864.005 -0,12 30,15 -101.967 86.349.751
2021-01-12 2021-01-08 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -9.027 2.867.387 -0,31 30,13 -271.984 86.394.370
2021-01-08 2021-01-07 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -16.141 2.876.414 -0,56 29,98 -483.907 86.234.892
2021-01-08 2021-01-06 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -95 2.892.555 0,00 31,36 -2.979 90.710.525
2021-01-08 2021-01-06 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -11.929 2.892.650 -0,41 30,09 -358.944 87.039.838
2021-01-06 2021-01-05 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -139 2.904.579 0,00 32,84 -4.565 95.386.374
2021-01-06 2021-01-05 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.017 2.904.718 -0,07 32,00 -64.544 92.950.976
2021-01-06 2021-01-05 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -11.168 2.906.735 -0,38 30,89 -344.980 89.789.044
2021-01-06 2021-01-04 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1.655 2.917.903 -0,06 33,55 -55.525 97.895.646
2021-01-06 2021-01-04 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -10.463 2.919.558 -0,36 32,57 -340.780 95.090.004
2021-01-06 3 OMEG Omega Alpha SPAC
Class B Ordinary Shares
2.735.000
2021-01-04 2020-12-31 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -151 2.930.021 -0,01 34,55 -5.217 101.232.226
2021-01-04 2020-12-31 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3.756 2.930.172 -0,13 33,84 -127.103 99.157.020
2021-01-04 2020-12-30 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -486 2.933.928 -0,02 33,75 -16.402 99.020.070
2021-01-04 2020-12-30 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3.769 2.934.414 -0,13 33,23 -125.244 97.510.577
2021-01-04 2020-12-30 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -7.730 2.938.183 -0,26 32,42 -250.607 95.255.893
2020-12-30 2020-12-29 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -54 2.945.913 0,00 32,87 -1.775 96.832.160
2020-12-30 2020-12-29 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -10.374 2.945.967 -0,35 31,75 -329.374 93.534.452
2020-12-30 2020-12-28 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -149 2.956.341 -0,01 33,25 -4.954 98.298.338
2020-12-30 2020-12-28 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -9.317 2.956.490 -0,31 32,34 -301.312 95.612.887
2020-12-28 2020-12-24 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -753 2.965.807 -0,03 33,25 -25.037 98.613.083
2020-12-28 2020-12-24 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -2.130 2.966.560 -0,07 32,48 -69.182 96.353.869
2020-12-28 2020-12-23 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -137 2.968.690 0,00 34,95 -4.788 103.755.716
2020-12-28 2020-12-23 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -313 2.968.827 -0,01 33,81 -10.583 100.376.041
2020-12-28 2020-12-23 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -8.692 2.969.140 -0,29 33,34 -289.791 98.991.128
2020-10-16 2020-10-14 4 KRON Kronos Bio, Inc.
Series Seed Preferred Stock
C - Conversion -1.522.484 0 -100,00
2020-10-16 2020-10-14 4 KRON Kronos Bio, Inc.
Convertible Promissory Note
C - Conversion 0
2020-10-16 2020-10-14 4 KRON Kronos Bio, Inc.
Series A Preferred Stock
C - Conversion -1.304.563 0 -100,00
2020-10-16 2020-10-14 4 KRON Kronos Bio, Inc.
Common Stock
P - Purchase 450.000 3.818.283 13,36 19,00 8.550.000 72.547.377
2020-10-16 2020-10-14 4 KRON Kronos Bio, Inc.
Common Stock
C - Conversion 366.299 3.368.283 12,20 16,15 5.915.729 54.397.770
2020-10-16 2020-10-14 4 KRON Kronos Bio, Inc.
Common Stock
C - Conversion 1.376.313 3.001.984 84,66
2020-10-16 2020-10-14 4 KRON Kronos Bio, Inc.
Common Stock
C - Conversion 1.606.220 1.625.671 8.257,78
2020-10-16 2020-10-14 4 KRON Kronos Bio, Inc.
Series Seed Preferred Stock
C - Conversion -1.522.484 0 -100,00
2020-10-16 2020-10-14 4 KRON Kronos Bio, Inc.
Convertible Promissory Note
C - Conversion 0
2020-10-16 2020-10-14 4 KRON Kronos Bio, Inc.
Series A Preferred Stock
C - Conversion -1.304.563 0 -100,00
2020-10-16 2020-10-14 4 KRON Kronos Bio, Inc.
Common Stock
P - Purchase 450.000 3.818.283 13,36 19,00 8.550.000 72.547.377
2020-10-16 2020-10-14 4 KRON Kronos Bio, Inc.
Common Stock
C - Conversion 366.299 3.368.283 12,20 16,15 5.915.729 54.397.770
2020-10-16 2020-10-14 4 KRON Kronos Bio, Inc.
Common Stock
C - Conversion 1.376.313 3.001.984 84,66
2020-10-16 2020-10-14 4 KRON Kronos Bio, Inc.
Common Stock
C - Conversion 1.606.220 1.625.671 8.257,78
2020-10-08 3 KRON Kronos Bio, Inc.
Common Stock
19.451
2020-10-08 3 KRON Kronos Bio, Inc.
Common Stock
19.451
2020-06-19 2020-06-18 4 MORF Morphic Holding, Inc.
Director Stock Option (right to buy)
A - Award 12.000 12.000
2020-04-03 2020-04-01 4 REPL Replimune Group, Inc.
Stock Option (Right to Buy)
A - Award 16.500 16.500
2019-11-20 2019-11-18 4 REPL Replimune Group, Inc.
Common Stock
P - Purchase 220.000 5.328.939 4,31 13,61 2.994.200 72.526.860
2019-09-18 2019-09-18 4 GOSS Gossamer Bio, Inc.
Common Stock
S - Sale -45.600 6.737.023 -0,67 21,88 -997.637 147.392.589
2019-09-18 2019-09-17 4 GOSS Gossamer Bio, Inc.
Common Stock
S - Sale -23.400 6.782.623 -0,34 21,62 -505.791 146.606.396
2019-09-18 2019-09-16 4 GOSS Gossamer Bio, Inc.
Common Stock
S - Sale -13.213 6.806.023 -0,19 21,52 -284.331 146.458.809
2019-09-12 2019-09-11 4 GOSS Gossamer Bio, Inc.
Common Stock
S - Sale -80.403 6.819.236 -1,17 21,31 -1.713.629 145.338.377
2019-09-12 2019-09-10 4 GOSS Gossamer Bio, Inc.
Common Stock
S - Sale -32.373 6.899.639 -0,47 21,00 -679.865 144.899.319
2019-09-09 2019-09-06 4 GOSS Gossamer Bio, Inc.
Common Stock
S - Sale -8.700 6.932.012 -0,13 21,51 -187.103 149.080.543
2019-09-09 2019-09-05 4 GOSS Gossamer Bio, Inc.
Common Stock
S - Sale -12.704 6.940.712 -0,18 21,60 -274.434 149.934.649
2019-07-01 2019-07-01 4 MORF Morphic Holding, Inc.
Series B Preferred Stock
C - Conversion -1.978.779 0 -100,00
2019-07-01 2019-07-01 4 MORF Morphic Holding, Inc.
Series A Preferred Stock
C - Conversion -857.470 0 -100,00
2019-07-01 2019-07-01 4 MORF Morphic Holding, Inc.
Common Stock
P - Purchase 133.333 2.969.582 4,70 15,00 1.999.995 44.543.730
2019-07-01 2019-07-01 4 MORF Morphic Holding, Inc.
Common Stock
C - Conversion 1.978.779 2.836.249 230,77
2019-07-01 2019-07-01 4 MORF Morphic Holding, Inc.
Common Stock
C - Conversion 857.470 857.470
2019-07-01 2019-07-01 4 MORF Morphic Holding, Inc.
Series B Preferred Stock
C - Conversion -1.978.779 0 -100,00
2019-07-01 2019-07-01 4 MORF Morphic Holding, Inc.
Series A Preferred Stock
C - Conversion -857.470 0 -100,00
2019-07-01 2019-07-01 4 MORF Morphic Holding, Inc.
Common Stock
P - Purchase 133.333 2.969.582 4,70 15,00 1.999.995 44.543.730
2019-07-01 2019-07-01 4 MORF Morphic Holding, Inc.
Common Stock
C - Conversion 1.978.779 2.836.249 230,77
2019-07-01 2019-07-01 4 MORF Morphic Holding, Inc.
Common Stock
C - Conversion 857.470 857.470
2019-06-26 3 MORF Morphic Holding, Inc.
No securities beneficially held
0
2019-06-26 3 MORF Morphic Holding, Inc.
No securities beneficially held
0
2019-06-11 2019-06-10 4 GOSS Gossamer Bio, Inc.
Stock Option (right to buy)
A - Award 23.500 23.500
2019-04-22 3 IMUX IMMUNIC, INC.
Common Stock
2.742.988
2019-04-22 3 IMUX IMMUNIC, INC.
Common Stock
2.742.988
2019-04-22 3 IMUX IMMUNIC, INC.
Common Stock
2.742.988
2019-04-22 3 IMUX IMMUNIC, INC.
Common Stock
2.742.988
2019-04-22 3 IMUX IMMUNIC, INC.
Common Stock
2.742.988
2019-04-22 3 IMUX IMMUNIC, INC.
Common Stock
2.742.988
2019-04-22 3 IMUX IMMUNIC, INC.
Common Stock
2.742.988
2019-04-22 3 IMUX IMMUNIC, INC.
Common Stock
2.742.988
2019-04-22 3 IMUX IMMUNIC, INC.
Common Stock
2.742.988
2019-04-22 3 IMUX IMMUNIC, INC.
Common Stock
2.742.988
2019-04-03 2019-04-01 4 REPL Replimune Group, Inc.
Employee Stock Option (Right to Buy)
A - Award 13.500 13.500
2019-02-12 2019-02-12 4 GOSS Gossamer Bio, Inc.
Series B Preferred Stock
C - Conversion -4.165.760 0 -100,00
2019-02-12 2019-02-12 4 GOSS Gossamer Bio, Inc.
Series A Preferred Stock
C - Conversion -7.124.620 0 -100,00
2019-02-12 2019-02-12 4 GOSS Gossamer Bio, Inc.
Series Seed Preferred Stock
C - Conversion -20.000.000 0 -100,00
2019-02-12 2019-02-12 4 GOSS Gossamer Bio, Inc.
Common Stock
C - Conversion 6.953.416 6.953.416
2018-07-25 2018-07-24 4 REPL Replimune Group, Inc.
Series B Convertible Preferred Stock
C - Conversion -101.896 0 -100,00
2018-07-25 2018-07-24 4 REPL Replimune Group, Inc.
Series A Convertible Preferred Stock
C - Conversion -259.366 0 -100,00
2018-07-25 2018-07-24 4 REPL Replimune Group, Inc.
Series Seed Preferred Stock
C - Conversion -100.000 0 -100,00
2018-07-25 2018-07-24 4 REPL Replimune Group, Inc.
Common Stock Warrants (right to buy)
C - Conversion 248.672 248.672
2018-07-25 2018-07-24 4 REPL Replimune Group, Inc.
Series Seed Warrants (right to buy)
C - Conversion -25.000 0 -100,00
2018-07-25 2018-07-24 4 REPL Replimune Group, Inc.
Common Stock
C - Conversion 1.013.547 4.854.783 26,39
2018-07-25 2018-07-24 4 REPL Replimune Group, Inc.
Common Stock
C - Conversion 2.579.881 3.841.236 204,53
2018-07-25 2018-07-24 4 REPL Replimune Group, Inc.
Common Stock
C - Conversion 994.688 1.261.355 373,01
2018-07-25 2018-07-24 4 REPL Replimune Group, Inc.
Common Stock
P - Purchase 266.667 266.667 15,00 4.000.005 4.000.005
2018-07-25 2018-07-19 4 REPL Replimune Group, Inc.
Common Stock Option
A - Award 13.500 13.500
2018-07-03 2018-07-02 4 TBIO Translate Bio, Inc.
Series C Preferred Stock
C - Conversion -302.173 0 -100,00
2018-07-03 2018-07-02 4 TBIO Translate Bio, Inc.
Series C Preferred Stock
C - Conversion -302.173 0 -100,00
2018-07-03 2018-07-02 4 TBIO Translate Bio, Inc.
Series B Preferred Stock
C - Conversion -2.000.103 0 -100,00
2018-07-03 2018-07-02 4 TBIO Translate Bio, Inc.
Series B Preferred Stock
C - Conversion -2.000.103 0 -100,00
2018-07-03 2018-07-02 4 TBIO Translate Bio, Inc.
Series A Preferred Stock
C - Conversion -5.800.000 0 -100,00
2018-07-03 2018-07-02 4 TBIO Translate Bio, Inc.
Series A Preferred Stock
C - Conversion -5.800.000 0 -100,00
2018-07-03 2018-07-02 4 TBIO Translate Bio, Inc.
Series C Preferred Stock
C - Conversion -1.263.484 0 -100,00
2018-07-03 2018-07-02 4 TBIO Translate Bio, Inc.
Series C Preferred Stock
C - Conversion -1.263.484 0 -100,00
2018-07-03 2018-07-02 4 TBIO Translate Bio, Inc.
Series B Preferred Stock
C - Conversion -1.676.348 0 -100,00
2018-07-03 2018-07-02 4 TBIO Translate Bio, Inc.
Series B Preferred Stock
C - Conversion -1.676.348 0 -100,00
2018-07-03 2018-07-02 4 TBIO Translate Bio, Inc.
Series A Preferred Stock
C - Conversion -2.500.000 0 -100,00
2018-07-03 2018-07-02 4 TBIO Translate Bio, Inc.
Series A Preferred Stock
C - Conversion -2.500.000 0 -100,00
2018-07-03 2018-07-02 4 TBIO Translate Bio, Inc.
Common Stock
C - Conversion 1.458.424 1.458.424
2018-07-03 2018-07-02 4 TBIO Translate Bio, Inc.
Common Stock
C - Conversion 1.458.424 1.458.424
2018-07-03 2018-07-02 4 TBIO Translate Bio, Inc.
Common Stock
C - Conversion 979.179 979.179
2018-07-03 2018-07-02 4 TBIO Translate Bio, Inc.
Common Stock
C - Conversion 979.179 979.179
2018-06-25 2018-06-25 4 KZR Kezar Life Sciences, Inc.
Series B Redeemable Convertible Preferred Stock
C - Conversion -377.783 0 -100,00
2018-06-25 2018-06-25 4 KZR Kezar Life Sciences, Inc.
Series B Redeemable Convertible Preferred Stock
C - Conversion -377.783 0 -100,00
2018-06-25 2018-06-25 4 KZR Kezar Life Sciences, Inc.
Series A Redeemable Convertible Preferred Stock
C - Conversion -315.489 0 -100,00
2018-06-25 2018-06-25 4 KZR Kezar Life Sciences, Inc.
Series A Redeemable Convertible Preferred Stock
C - Conversion -315.489 0 -100,00
2018-06-25 2018-06-25 4 KZR Kezar Life Sciences, Inc.
Common Stock
C - Conversion 377.783 693.272 119,75
2018-06-25 2018-06-25 4 KZR Kezar Life Sciences, Inc.
Common Stock
C - Conversion 377.783 693.272 119,75
2018-06-25 2018-06-25 4 KZR Kezar Life Sciences, Inc.
Common Stock
C - Conversion 315.489 315.489
2018-06-25 2018-06-25 4 KZR Kezar Life Sciences, Inc.
Common Stock
C - Conversion 315.489 315.489
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
12.043.945
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
11.328.690
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
2014-11-10 3 PRTK Paratek Pharmaceuticals, Inc.
Common Stock
13.072.375
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)